Trial · NCT03557307
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Patients Who Achieve 100% Reduction in Daily OCS Dose | Benra 30 mg | 376 | Participants | ||
| Patients Who Achieve 100% Reduction or a Daily OCS Dose of <=5mg | Benra 30 mg | 490 | Participants | ||
| Patients Who Achieve a Daily OCS of ≤5mg | Benra 30 mg | 547 | Participants | ||
| Patients Who Achieve a ≥90%, ≥75%, and ≥50% Reduction in Daily OCS Dose | Benra 30 mg | ≥90% reduction | 383 | Participants | |
| Patients Who Achieve a ≥90%, ≥75%, and ≥50% Reduction in Daily OCS Dose | Benra 30 mg | ≥75% reduction | 412 | Participants | |
| Patients Who Achieve a ≥90%, ≥75%, and ≥50% Reduction in Daily OCS Dose | Benra 30 mg | ≥50% reduction | 489 | Participants | |
| Change From Baseline in Average Daily OCS Dose (mg) | Benra 30 mg | -8.50 | 95% Confidence Interval -9.10 to -7.90 | mg | |
| Patients Who Achieve 100% Reduction in Daily OCS Dose From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy | Asthma Treatment as Per Healthcare Provider Discretion | 138 | Participants | ||
| Patients Who Achieve 100% Reduction in Daily OCS Dose From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy | >=50% Any Biologic | 60 | Participants | ||
| Patients Who Achieve 100% Reduction in Daily OCS Dose From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy | >=50% Benra | 54 | Participants | ||
| Patients Who Achieve a Daily OCS Dose of ≤5 mg at the End of the Long Term Follow up Substudy | Asthma Treatment as Per Healthcare Provider Discretion | 177 | Participants | ||
| Patients Who Achieve a Daily OCS Dose of ≤5 mg at the End of the Long Term Follow up Substudy | >=50% Any Biologic | 72 | Participants | ||
| Patients Who Achieve a Daily OCS Dose of ≤5 mg at the End of the Long Term Follow up Substudy | >=50% Benra | 65 | Participants | ||
| Patients Who Achieve ≥90%, ≥75%, ≥50% or >0% OCS Reduction From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy | Asthma Treatment as Per Healthcare Provider Discretion | >=90% reduction | 141 | Participants | |
| Patients Who Achieve ≥90%, ≥75%, ≥50% or >0% OCS Reduction From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy | >=50% Any Biologic | >=90% reduction | 61 | Participants | |
| Patients Who Achieve ≥90%, ≥75%, ≥50% or >0% OCS Reduction From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy | >=50% Benra | >=90% reduction | 55 | Participants | |
| Patients Who Achieve ≥90%, ≥75%, ≥50% or >0% OCS Reduction From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy | Asthma Treatment as Per Healthcare Provider Discretion | >=75% reduction | 151 | Participants | |
| Patients Who Achieve ≥90%, ≥75%, ≥50% or >0% OCS Reduction From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy | >=50% Any Biologic | >=75% reduction | 64 | Participants | |
| Patients Who Achieve ≥90%, ≥75%, ≥50% or >0% OCS Reduction From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy | >=50% Benra | >=75% reduction | 58 | Participants | |
| Patients Who Achieve ≥90%, ≥75%, ≥50% or >0% OCS Reduction From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy | Asthma Treatment as Per Healthcare Provider Discretion | >=50% reduction | 172 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03557307/results